Healthcare / BiotechnologyShanghai
$8.01
+0.23 (+2.96%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-12.2M · quality 47.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.3B
P/E
N/A
•EV/EBITDA
64.0x
↑ROE
-1.5%
↓Gross Margin
56.8%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.3%
FCF CAGR
—
FCF margin
-4.2%
FCF / Net income
0.59x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $288.3M · net income $-20.5M · FCF $-12.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $288.3M | $288.3M | $303.4M | $301.5M | $328.6M |
| Net Income | $-20.5M | $-20.5M | $-44.7M | $31.5M | $61.1M |
| EBITDA | $49.6M | $49.6M | $11.9M | $95.9M | $136.4M |
| EPS | -0.05 | -0.05 | -0.11 | 0.08 | 0.15 |
| Gross Margin | 56.8% | 56.8% | 60.2% | 70.8% | 75.2% |
| Operating Margin | -4.9% | -4.9% | -7.7% | 10.8% | 24.1% |
| Net Margin | -7.1% | -7.1% | -14.7% | 10.5% | 18.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Current Ratio | 4.00 | 4.00 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-12.2M | $-12.2M | $4.5M | $-126.1M | $-84.0M |
| Returns | |||||
| ROE | -1.5% | -1.5% | -3.2% | 2.1% | 4.1% |
| Valuation | |||||
| P/E | — | — | — | 90.25 | 54.27 |
| EV/EBITDA | 63.96 | 63.96 | 161.14 | 29.19 | 23.93 |
| P/B | 2.36 | 2.36 | 1.45 | 1.91 | 2.22 |
| Growth & Yield | |||||
| Revenue Growth | -5.0% | -5.0% | 0.6% | -8.2% | — |
| EPS Growth | 54.5% | 54.5% | -237.5% | -46.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+36.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.11 → -0.05
Residual
+36.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.